Tool Create startup animated videos in minutes, not in hours! 

Programmable genetics gets more cash as Tessera Therapeutics gets a $230 million infusion – TechCrunch

Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with $230 million in new financing to build up its platform for better biological programming. The thesis is similar to the approach taken by companies like Senti Bio, another early-stage biotech company that raised $105 million earlier this month. The company asserts that this represents a breakthrough in genetic engineering, which can build better therapies. Gene writing is inspired by and builds upon the shoulders of nature’s most prevalent class of genes: mobile genetic elements. The company said it can also write entirely new sequences into the genome by delivering only RNA.

Startup Around is now on Telegram and Whatsapp. For the best startup stories & resources, subscribe us on Telegram & Whatsapp.
Get the best stories from Startup Around on Telegram